21:56 , Jun 28, 2019 |  BC Extra  |  Clinical News

June 28 Clinical Quick Takes: Imfinzi extends survival in Phase III SCLC study; plus LSK, Pfizer, FibroGen, Aclaris and more

AZ's Imfinzi shows survival benefit in Phase III for SCLC  AstraZeneca plc (LSE:AZN; NYSE:AZN) said an interim analysis of the Phase III CASPIAN trial showed Imfinzi plus etoposide and platinum-based chemotherapy met the primary endpoint...
23:54 , Nov 29, 2018 |  BC Extra  |  Preclinical News

Chemputer automates drug synthesis

A University of Glasgow team developed an app-controlled robotic platform that enables the automated chemical synthesis and purification of drugs by including software that converts written chemistry protocols into code that drives production. Manual chemical...
03:01 , Sep 1, 2018 |  BioCentury  |  Politics, Policy & Law

A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
20:06 , Jul 11, 2018 |  BC Extra  |  Politics & Policy

Pfizer creates deadline for Trump drug plan

Pfizer Inc. (NYSE:PFE) Chairman and CEO Ian Read has turned President Donald Trump’s fury over drug price increases into an opportunity to create a de facto deadline for the Trump administration to implement its drug...
22:53 , Jul 9, 2018 |  BC Extra  |  Company News

Trump blasts Pfizer for price hikes, threatens to respond

President Donald Trump threatened to take action against companies for increasing drug prices in a tweet Monday that specifically named Pfizer Inc. (NYSE:PFE). Trump tweeted, “Pfizer & others should be ashamed that they have raised...
07:00 , Oct 24, 2016 |  BioCentury  |  Strategy

Lilly’s history lesson

  Eli Lilly and Co. President and CEO-in-waiting David Ricks will inherit a well-stocked pipeline, seven drugs less than three years old and a much-improved growth trajectory. To maintain momentum, he’ll have to execute on...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Company News

NuSirt Biopharma, OWL deal

The companies partnered to develop diagnostic tools for trials of NuSirt’s Phase II candidate NS-0200 in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The product is a fixed-dose combination of leucine, metformin and...
07:00 , Jun 23, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Endothelial cell nitric oxide synthase 3 (NOS3; eNOS)

Genitourinary disease INDICATION: Genitourinary Patient sample and mouse studies suggest promoting NOS3 activity with Viagra sildenafil could help prevent preeclampsia. In patient placental tissue samples or vascular endothelium from a mouse model of preeclampsia, markers...
07:00 , Jun 23, 2016 |  BC Innovations  |  Tools & Techniques

Home is in the placenta

Many drug developers have avoided stepping into what they see as the high risk area of pregnancy-associated complications, leaving diseases such as preeclampsia and fetal growth restriction with little innovation and few treatment options. By...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Clinical News

SST-6007: Phase II started

Strategic Science and Technologies began a double-blind, placebo-controlled, 2-way crossover, U.S. Phase II trial to evaluate single doses of topical SST-6007 in about 30 patients. Strategic Science and Technologies LLC , Cambridge, Mass.   Product:...